The global infectious disease diagnostics market is projected to witness strong expansion over the next decade, supported by the rising prevalence of communicable diseases and increasing investments in healthcare infrastructure worldwide. The market is expected to grow steadily, reaching approximately USD 46.2 billion by 2035, registering a CAGR of 7.2%, according to the latest analysis by Future Market Insights (FMI).
Market growth is being shaped by increasing government funding for disease surveillance, growing public awareness regarding early detection, and the rapid adoption of advanced testing technologies. Diagnostic systems have evolved from specialized laboratory tools into critical front-line components of pandemic preparedness and routine clinical workflows. While traditional testing methods continue to support foundational healthcare, manufacturers are increasingly integrating advanced systems such as molecular diagnostics, polymerase chain reaction (PCR), and next-generation sequencing (NGS) to comply with modern healthcare expectations and improve patient outcomes.
Infectious Disease Diagnostics Market Snapshot (2025–2035)
- Market size outlook toward 2035: USD 46.2 billion
- Forecast CAGR: 7.2%
- Dominant product category: Assays & Reagents (47.5% market share)
- Fastest-growing / Leading segment: Immunodiagnostics technology (~41.6% share)
- Key growth regions: North America, Asia-Pacific, Europe
- Primary demand channel: Centralized laboratories and point-of-care settings
Momentum in the Market
Beginning from steady global adoption levels, the infectious disease diagnostics market demonstrates accelerated growth throughout the forecast period as diagnostic compliance and pandemic preparedness become mandatory across multiple countries. Between 2026 and 2035, expanding global travel and rising population density are expected to significantly boost demand for integrated diagnostic systems. Increasing urbanization and higher traffic density across borders are encouraging governments and healthcare systems to prioritize early pathogen detection technologies.
From 2035 onward, innovation in intelligent diagnostic platforms and integration with digital health systems is expected to further strengthen market expansion. Point-of-care testing systems capable of delivering rapid, accurate results outside traditional laboratory settings are emerging as key differentiators in modern medical diagnostics.
The Reasons Behind the Market’s Growth
Demand for infectious disease diagnostics is rising due to multiple structural and technological factors reshaping the global healthcare ecosystem.
Global Resurgence of Communicable Diseases The increasing incidence of infectious diseases such as COVID-19, HIV, tuberculosis, malaria, and influenza has heightened the demand for effective diagnostic tools to contain outbreaks.
Technological Advancements in Molecular Diagnostics Innovations in PCR, next-generation sequencing (NGS), and microfluidics are allowing for rapid, high-sensitivity pathogen identification, accelerating adoption across clinical settings.
Government Initiatives and Public Funding Governments worldwide are investing heavily in laboratory infrastructure, national screening programs, and pandemic response frameworks to secure public health.
Rising Demand for Point-of-Care (POC) Testing The shift toward decentralized healthcare is driving the adoption of rapid testing kits that provide actionable results directly at the patient's bedside or in remote areas.
Top Segment Application Type
Assays & Reagents Lead Market Demand Assays & Reagents account for the majority of the market volume, supported by the high-frequency consumption of testing kits and consumables required for daily laboratory operations.
Disease and Technology Analysis
- Human Immunodeficiency Virus (HIV): Captures 34.8% of the revenue, driven by international funding for routine viral load monitoring and universal screening access.
- Immunodiagnostics: Represents 41.6% of technology adoption, favored for its cost-effectiveness and widespread use in ELISA and lateral flow assays.
- Clinical Microbiology & PCR: Expanding steadily as clinical laboratories upgrade to automated, multiplex-capable testing platforms.
- Emerging Pathogens: Accelerating the demand for flexible, scalable diagnostic platforms capable of adjusting to new viral or bacterial strains.
Regional Development: Advanced Infrastructure and Reforms Drive Expansion
The global diagnostics landscape is shifting toward localized manufacturing and advanced regional networks to improve diagnostic supply chains.
- United States: The market benefits from a robust Centers for Disease Control and Prevention (CDC) infrastructure, strong institutional collaborations, and extensive insurance reimbursement coverage.
- China: Rapidly expanding due to extensive healthcare reforms, targeted national programs for tuberculosis and hepatitis, and a booming domestic biotechnology sector.
- United Kingdom & Europe: Growth is fueled by centralized healthcare systems, structured public health initiatives, and early adoption of clinical trial innovations.
Challenges, Trends, Opportunities, and Drivers
Drivers
- High prevalence of infectious and respiratory diseases
- Increased international travel and cross-border disease transmission
- Growing aging population vulnerable to opportunistic infections
- Substantial funding for healthcare R&D and surveillance
Opportunities
- Development of digital result interpretation tools
- Multiplex assays capable of testing co-infections simultaneously
- Expansion of affordable diagnostic access in underserved rural areas
- AI-enabled diagnostic tools for early outbreak prediction
Trends
- Transition toward home-based self-testing kits
- Integration of automated instruments to reduce lab technician dependency
- Growth of sustainable and recyclable material usage in consumables
- Rising application of NGS for tracking viral mutations
Challenges
- High cost pressures associated with entry-level molecular systems
- Complex regulatory compliance across different international borders
- Limited laboratory infrastructure in low-income medical facilities
Country Growth Outlook
The market’s growth trajectory is closely tied to industrial medical modernization and national health policies:
- United States: Focuses on molecular innovation and rapid deployment.
- China: Emphasizes point-of-care expansion in rural provinces.
- United Kingdom: Prioritizes centralized public health diagnostic rollouts.
- India & Brazil: Expanding basic infectious disease testing availability.
The Competitive Environment
The global infectious disease diagnostics market is moderately consolidated, with leading healthcare technology providers competing through product innovation, strategic acquisitions, and manufacturing expansion. Leading companies include:
- Abbott Laboratories
- BioMérieux SA
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- Siemens Healthineers
- Thermo Fisher Scientific
These players are investing heavily in automated multiplex platforms, decentralized molecular testing devices, and cloud-integrated data systems while forming partnerships with regional healthcare distributors to secure supply lines.
Future Outlook: Toward Intelligent and Faster Disease Management
The infectious disease diagnostics market is entering a transformative decade shaped by automation, molecular sensitivity, and decentralized care models. Future diagnostic systems are expected to function as highly integrated modules working alongside telehealth networks to enable instant epidemiological reporting. As global healthcare infrastructure matures and preventative screening protocols strengthen, diagnostic technologies will remain central to achieving safer, healthier, and more resilient societies worldwide.
For a comprehensive strategic outlook and detailed analysis of technological developments shaping the industry, readers can explore the full report on the official Future Market Insights website: https://www.futuremarketinsights.com/reports/infectious-disease-diagnostics-market
